Safe Harbor Statement · Safe Harbor Statement This presentation may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. (“the

Safe Harbor StatementThis presentation may contain forward-looking statements, including information

about management's view of Flow Pharma, Inc. (“the Company”), future

expectations, plans and prospects. In particular, when used in the preceding

discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or

“may,” and similar conditional expressions are intended to identify forward-looking

statements. Any statements made in this presentation other than those of historical

fact, about an action, event or development, are forward-looking statements.

These statements involve known and unknown risks, uncertainties and other factors,

which may cause the results of the Company, its subsidiaries and concepts to be

materially different than those expressed or implied in such statements. Unknown

or unpredictable factors also could have material adverse effects on the Company’s

future results. The forward-looking statements included in this presentation are

made only as of the date hereof. The Company cannot guarantee future results,

levels of activity, performance or achievements. Accordingly, you should not place

undue reliance on these forward-looking statements. Finally, the Company

undertakes no obligation to update these statements after the date of this release,

except as required by law, and also takes no obligation to update or correct

information prepared by third parties that are not paid for by Flow Pharma, Inc.

Reid Rubsamen, M.D., CEO, Director

Speaker

Computer Science

Medicine

222

Differentiating Technology

FlowVax™ is a patented,

adjuvanted microsphere therapeutic

peptide vaccine platform

Differentiating Technology

FlowVax™ is a room temperature

stable dry powder that can be

delivered via nasal administration

Federal Grant Application Process• Identify a relevant grant

• Find a partner (if STTR)• Identify key internal/external (if STTR) players for

preparing the submission

• Officers

• CFO

• Lawyer

• Scientists

• Manufacturing

• Identify key government representatives• Granting agency

• Contracting officer (KO)

• Allocate grant writing tasks

• Manage grant writing tasks

• Submit the grant

Federal Grant Application Process• Manage the process

• Timely updates

• Reporting: On Time / On Budget

• TCONs

• Closeout

• Defense Technology Information Center (DTIC)

• Apply for the next cycle

• Same agency (STTR)?

• Different agency?

Federal Grant Application Process

Key Points

• Finding the relevant grant

• Technical grant writing / processing

• Project management

• Don’t hide in your laboratory

• BARDA / TechWatch / Other

Flow Pharma Filovirus Program

FlowVax Ebola™

• Self Funded

• Topic for TechWatch Meeting

FlowVax Marburg™

• Marburg Virus Medical Countermeasure

Chemical and Biological Defense (CBD) / STTR

• Phase 1 (complete)

• STTR Phase 2 (funding pending)

Flow Pharma Breast Cancer Program

FlowVax BreastCA™

• Personalized Therapeutic Vaccine for Breast

Cancer

• Applied for DoD grant

The Filovirus Threat Direction

• Foreign actors have weaponized Marburg virus

for aerosol delivery

• Lung Tissue + Filovirus Antibody + Aerosolized

Virus Exposure = Death

• FlowVax™ is a peptide vaccine

• TechWatch Meeting

Two Peptides Can Compete

Size Exclusion Antigen Presentation Control




FlowVax Ebola™

0 5 10 15 20 250

50

100

Days post Infection

Per

cen

t su

rviv

al

Survival After 1,000 PFU Challenge

Active versus PBS Control

1,000 PFU (PBS Control)

1,000 PFU (Active)

FlowVax Ebola™

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 2015

20

25

30

35

Days Post-Infection

Mo

use

Bo

dy

Wei

gh

t (g

)

1,000 PFU (Active Microspheres) Body Weights

FlowVax Ebola™

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 2015

20

25

30

35

Days Post-Infection

Mo

use

Bo

dy

Wei

gh

t (g

)

1,000 PFU (PBS Control) Body Weights

11111111111152

333

Video Showing FlowVax Microspheres

and Antigen Presenting Cells in Culture

11111111111152

333

11111111111152

333

Patent Number

Country Title Type Issue Date

Expiration Date

10,172,936 USA Peptide Particle Formulation

Composition of Matter

2019 2031

9,408,906 USA Peptide Particle Formulation


2016 2031

2012229234 Australia Vaccine Formulation of Mannose Coated Particles


2016 2032

2011261203 Australia Peptide Particle Formulation


2011 2031

2,801,585 Canada Peptide Particle Formulation


2017 2034

2,575,869 European Union Peptide Particle Formulation


2017 2031

FlowVax™ Adjuvanted Microspheres

The Neoantigen Space

What Immuno Oncology Should Be:

• Safe

• Inexpensive

• Broadly Applicable

Pipeline Product

• FlowVax BreastCA™

• Personalized design

• Partners for gene sequencing

and neoantigen identification

• Breast cancer gene sequencing

study underway in the US

Tumor-Specific Neoantigen Based Therapy1. Sequence normal tissue and

tumor tissue - identify

mutations present on

expressed tumor (but not

normal) samples.

2. Use AI to find mutated

peptides likely to elicit a

killer T-cell response

(neoantigens) based on

public and proprietary data.

3. Manufacture and dose

patient-specific

therapeutic vaccine.

11111111111152

333

Mouse Triple Negative Breast Cancer

11111111111152

333



11111111111152

333


11111111111152

333


Flow Pharma Gene Sequencing Study

Flow Pharma Gene Sequencing Study

Timeline

Q12020

Q22020

Q32020

Q42020

Proof of PrincipalCompleted

FlowVax HPVPhase I/II

FlowVaxPre-Clinical Safety

FlowVax HPVPhase I/II Screening

Breast Cancer Gene Sequencing Study

FlowVax GMP Manufacturing

FlowVax BreastCAPhase I/II

Safe Harbor Statement · Safe Harbor Statement This presentation may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. (“the

Documents